Overview

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This phase II study investigating the efficacy and safety of a combination of biaxin,lenalidomide and dexamethasone in subjects with relapsed/refractory MM.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
China Food and Drug Administration
Treatments:
BB 1101
Clarithromycin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide